Bristol-myers Squibb Compnay

Five Prime Therapeutics, Inc.

Gilead Sciences, Inc.

Richard Y Huang

Guodong Chen

Alan J Korman

Mohan Srinivasan

Mark J Selby

Karla Ann Henning

Haichun Huang

Nils Lonberg

Michelle Minhua Han

Huiming Li

Ginger Chao Rakestraw

Changyu Wang

Indrani Chakraborty

Ekaterina G Deyanova

Christine Bee

Bryan C Barnhart

Paul O Sheppard

Shrikant Deshpande

Xiao Min Schebye

Susan Wong

Aaron Paul Yamniuk

Ming Lei

Sandra V Hatcher

Hong-An Truong

Liang Schweizer

Maria N Jure-Kunkel

Brigitte Devaux

Martin J Corbett

Michelle Renee Kuhne

Daniel F Ardourel

John S Sack

Andrew Rankin

Andy X Deng

Anan Chuntharapai

Xiaodi Deng

Natalie Bezman

Emanuela Sega

Angela Goodenough

Joseph E Myers, Jr

Joseph Toth

Pingping Zhang

Arvind Rajpal

Vangipuram S Rangan

Xiang Shao

Susan Chien-Szu Wong

Amy D Jhatakia

Dasa Lipovsek

Michael L Mitchell

Lianhong Xu

Stanley Richard Krystek, Jr

Ryan McFadden

Linda Liang

Xi-Tao Wang

Keith Sadoon Bahjat

Steven Sheriff

Robert J Johnston

Lin Hui Su

Irvith M Carvajal

Luis Borges

John P Throup

Christina Terragni

Qihong Zhao

Jason Robert Pinckney

Diana Yuhui Chen

Steven R O'Neil

John Thomas Loffredo

Huadong Sun

Cristian Rodriguez

Rose A Dibella

Olufemi A Adelakun

James G Taylor

Hyung-Jung Pyun

Hong Yang

Randall Halcomb

Eda Y Canales

Rick Andrew Lee

Hongtao Liu

Hongyan Guo

Pavel Strop

Gediminas J Brizgys

Petr Jansa

Paul A Roethle

Robert F Graziano

Adam James Schrier

Michael Sangi

Xiaowu Chen

Roland D Saito

Joshua J Van Veldhuizen

Kerim Babaoglu

Zhenhong R Cai

Xiaochun Han

Daniel H Byun

Jennifer Alissa Loyer-Drew

Akbar Nayeem

Li-Sheng Lu

Michael Quigley

Marina Shatskikh

Jun Zhang

Yingmei Qi

Hadia Lemar

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Antibodies binding to ILT4

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Antibodies against TIM3 and uses thereof

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Antibodies binding to vista at acidic pH

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

Anti-CD27 antibodies and uses thereof

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)

The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Inhibitors of peptidylarginine deiminases

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

IP-10 antibodies and their uses

Provided herein are polypeptides which include tenth fibronectin type III domains (Fn3) that bind to glypican-3. Also provided are fusion molecules comprising aFn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3Fn3 drug conjugates are also provided.

Glypican-3-binding fibronectin based scaffold molecules

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Anti-GITR antibodies for cancer diagnostics

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against CD73 and uses thereof

Growing community of inventors

Bridgewater, NJ, United States of America

Richard Y Huang